AMGN

Amgen (AMGN)

Amgen Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:AMGN

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/12/11	06 : 30	PR Newswire (US)	AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND	NASDAQ:AMGN	Amgen Inc
2024/12/08	00 : 00	PR Newswire (US)	BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)	NASDAQ:AMGN	Amgen Inc
2024/12/07	08 : 17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AMGN	Amgen Inc
2024/12/05	23 : 00	PR Newswire (US)	AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA	NASDAQ:AMGN	Amgen Inc
2024/12/04	09 : 48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AMGN	Amgen Inc
2024/12/03	06 : 00	PR Newswire (US)	AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE	NASDAQ:AMGN	Amgen Inc
2024/11/30	06 : 30	PR Newswire (US)	AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE	NASDAQ:AMGN	Amgen Inc
2024/11/26	21 : 05	PR Newswire (US)	AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY	NASDAQ:AMGN	Amgen Inc
2024/11/26	21 : 00	PR Newswire (US)	AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM	NASDAQ:AMGN	Amgen Inc
2024/11/21	06 : 00	PR Newswire (US)	AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT	NASDAQ:AMGN	Amgen Inc
2024/11/15	06 : 00	PR Newswire (US)	AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024	NASDAQ:AMGN	Amgen Inc
2024/11/14	05 : 27	PR Newswire (US)	MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM	NASDAQ:AMGN	Amgen Inc
2024/11/13	19 : 00	PR Newswire (US)	AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA	NASDAQ:AMGN	Amgen Inc
2024/11/09	06 : 00	PR Newswire (US)	AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE	NASDAQ:AMGN	Amgen Inc
2024/11/08	16 : 00	PR Newswire (US)	TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS	NASDAQ:AMGN	Amgen Inc
2024/11/07	09 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AMGN	Amgen Inc
2024/11/07	09 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AMGN	Amgen Inc
2024/11/07	09 : 41	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AMGN	Amgen Inc
2024/11/07	09 : 38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AMGN	Amgen Inc
2024/11/07	09 : 37	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AMGN	Amgen Inc
2024/10/31	20 : 13	IH Market News	Microsoft and Meta Decline Up to 4%; Roku Falls 14% Amid Lower Estimates; Booking Surges 6%; Carvana Soars 20%	NASDAQ:AMGN	Amgen Inc
2024/10/31	05 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMGN	Amgen Inc
2024/10/31	05 : 01	PR Newswire (US)	AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS	NASDAQ:AMGN	Amgen Inc
2024/10/26	05 : 00	PR Newswire (US)	AMGEN ANNOUNCES 2024 FOURTH QUARTER DIVIDEND	NASDAQ:AMGN	Amgen Inc
2024/10/25	05 : 00	PR Newswire (US)	AMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTS	NASDAQ:AMGN	Amgen Inc
2024/10/15	21 : 00	PR Newswire (US)	AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024	NASDAQ:AMGN	Amgen Inc
2024/10/01	22 : 00	PR Newswire (US)	LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE	NASDAQ:AMGN	Amgen Inc
2024/09/26	05 : 45	IH Market News	Dow, S&P Come Off Record Highs, Close On Weak Note	NASDAQ:AMGN	Amgen Inc
2024/09/25	05 : 00	PR Newswire (US)	TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE	NASDAQ:AMGN	Amgen Inc
2024/09/24	05 : 00	PR Newswire (US)	AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE	NASDAQ:AMGN	Amgen Inc